NCT01613703

ONO-2952 Single-dose PET Study in Healthy Adult Subjects

Open-Label, Single-Center, Single Dose Positron Emission Topography (PET) Using [11C]PBR28 to Evaluate Brain Translocator Protein 18KDa (TSPO) Occupancy of ONO-2952 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Ono Pharma USA Inc · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the brain TSPO occupancy of ONO-2952 in healthy adult subjects after a single dose using \[11C\]PBR28 as a specific PET ligand for TSPO. The secondary objective is to evaluate the relationship between TSPO occupancy and the plasma concentration of ONO-2952 and to investigate the safety and tolerability of ONO-2952 in healthy subjects.

Conditions

• Healthy Adult Subjects

Interventions

Type	Name	Description
DRUG	ONO-2952	1 mg to 200 mg QD at a single descending dose

Timeline

• Start date: 2012-08-01
• Primary completion: 2013-03-01
• First posted: 2012-06-07
• Last updated: 2013-06-03

Locations

1 site across 1 country: United States